Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs

Sep 27 2016

• By Mandy Jackson

ApproveOnKeyboard_1200x675

Related Content

Crohn's Pipeline: Janssen Seeks New Niche For Stelara As Biologics Use Rises

Mar 19 2016

TiGenix The Latest Partner In Takeda Deal Frenzy

Jul 06 2016

Celgene Diversifying Beyond Myeloma Backbone Revlimid

Jan 29 2016

Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira

Sep 24 2016

Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors

Sep 13 2016

INFOGRAPHIC: RA pipeline has limited new options

Jul 30 2015

Evolving Takeda Signals Intent To Build Around Entyvio, GI Franchise

Jul 11 2016

Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017

Jul 19 2016

Related Companies

Johnson & Johnson

Johnson & Johnson

Takeda Pharmaceutical Co. Ltd.

Biogen, Inc.

AbbVie Inc.

UCB S.A.

University of California, San Diego

Express Scripts Holding Company

Amgen, Inc.

Takeda Pharmaceutical Co. Ltd.

Roche Holding AG

Bristol Myers Squibb Company

Nogra Pharma Ltd.

RedHill Biopharma Ltd.

Bausch Health Companies Inc.

Alfa Wassermann SpA

Additional Topics

Approvals Reimbursement Commercial Gastrointestinal Inflammation BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window